Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Arcapta Neohaler (indacaterol) and Brovana (arformoterol) are both long-acting beta-agonists (LABAs) used to help people with chronic obstructive pulmonary disease (COPD) breathe easier. However, there are some key differences between the two. Arcapta Neohaler (indacaterol) was available as an inhaler but has been discontinued and is no longer available in the U.S. In contrast, Brovana (arformoterol) is still available and is used with a nebulizer, which turns the medication into a mist that you inhale. You need to use Brovana (arformoterol) twice a day, while Arcapta Neohaler (indacaterol) was typically used once a day. Additionally, Brovana (arformoterol) has been shown to lower the risk of hospitalizations due to worsening COPD symptoms, while such specific benefits were not mentioned for Arcapta Neohaler (indacaterol). Lastly, Brovana (arformoterol) requires careful storage and handling, including refrigeration, which was not noted for Arcapta Neohaler (indacaterol).
Arcapta neohaler (indacaterol)
Arformoterol (Brovana)
Arcapta neohaler (indacaterol)
Arformoterol (Brovana)
Summary of Indacaterol vs. Brovana
Summary for LABA
Arcapta Neohaler (indacaterol) controls your chronic obstructive pulmonary disease (COPD) and helps you breathe easier. It is no longer available and has been replaced by newer inhalers.